Innoviva, Inc. Files 8-K on Financials
Ticker: INVA · Form: 8-K · Filed: Feb 29, 2024 · CIK: 1080014
| Field | Detail |
|---|---|
| Company | Innoviva, INC. (INVA) |
| Form Type | 8-K |
| Filed Date | Feb 29, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k, operations
TL;DR
Innoviva dropped its 8-K financials today, check it out.
AI Summary
Innoviva, Inc. filed an 8-K on February 29, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, providing an update on the company's financial performance. Innoviva, Inc. is a pharmaceutical preparations company incorporated in Delaware.
Why It Matters
This 8-K filing provides investors with crucial updates on Innoviva's financial performance and condition, enabling informed investment decisions.
Risk Assessment
Risk Level: low — This filing is a routine financial disclosure and does not indicate any immediate or significant risks.
Key Players & Entities
- Innoviva, Inc. (company) — Registrant
- February 29, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 1350 Old Bayshore Highway, Suite 400 (address) — Business Address
- Burlingame, California (location) — City and State of Business Address
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Innoviva, Inc.'s results of operations and financial condition, including financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on February 29, 2024.
In which state is Innoviva, Inc. incorporated?
Innoviva, Inc. is incorporated in Delaware.
What is Innoviva, Inc.'s business address?
Innoviva, Inc.'s business address is 1350 Old Bayshore Highway, Suite 400, Burlingame, California 94010.
What is the Standard Industrial Classification (SIC) code for Innoviva, Inc.?
The Standard Industrial Classification (SIC) code for Innoviva, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 526 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-02-29 16:15:48
Key Financial Figures
- $0.01 — ch registered Common Stock, par value $0.01 per share INVA The NASDAQ Global Se
Filing Documents
- tm247467d1_8k.htm (8-K) — 24KB
- tm247467d1_ex99-1.htm (EX-99.1) — 125KB
- tm247467d1_ex99-1img001.jpg (GRAPHIC) — 11KB
- 0001104659-24-029378.txt ( ) — 346KB
- inva-20240229.xsd (EX-101.SCH) — 3KB
- inva-20240229_lab.xml (EX-101.LAB) — 33KB
- inva-20240229_pre.xml (EX-101.PRE) — 22KB
- tm247467d1_8k_htm.xml (XML) — 4KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition On February 29, 2024, Innoviva, Inc. (the "Company") issued a press release regarding its results of operations and financial condition for the quarter ended December 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report. The information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits (d) Exhibits 99.1 Press Release dated February 29, 2024 104 Cover Page Interactive File (the cover page tags are embedded within the Inline XBRL document) - 2 - SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INNOVIVA, INC. Date: February 29, 2024 By: /s/ Pavel Raifeld Pavel Raifeld Chief Executive Officer - 3 -